- Psychedelic Journal Watch
- Posts
- Psychedelic Journal Watch
Psychedelic Journal Watch
Keeping health professionals abreast of the latest research in psychedelic medicine
I. DMT for Major Depressive Disorder (MDD)
One dose of DMT produces a significant reduction in depressive symptoms, according to Nature.
In this phase II, double blind, randomized controlled trial, 34 participants with MDD were given either DMT or active placebo combined with psychotherapy.
After two weeks, individuals who received DMT showed a significant reduction in depressive symptoms compared to the placebo group. The reduction in depressive symptoms were sustained after 3 months.
According to the authors, “a single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to 3 months. The treatment was well-tolerated and safe.”
II. Microdosing LSD for Major Depressive Disorder (MDD)
Microdosing LSD leads to long-lasting reduction in depression symptoms, according to the Journal of Neuropharmacology.
In this open-label study, 19 participants with MDD were given 6 – 20 micrograms of LSD twice weekly for 8 weeks.
Depressive symptoms were reduced by 58% and were sustained for up to 6 months. Improvements were also measured in anxiety, rumination, stress, and quality of life.
According to the authors, “while limited by an open-label design and small sample size, this study provides preliminary evidence supporting the safety and feasibility of treating moderate depression with microdosed LSD and underscores a need for further randomised controlled trials.”
III. Psilocybin for Chronic Lyme Disease
Psilocybin-assisted therapy improves symptoms and quality of life in people with chronic Lyme disease, according to Scientific Reports.
In this open-label pilot study, 20 participants with well-documented chronic Lyme disease, received 2 psilocybin sessions combined with psychological support over the course of 8 weeks.
At 6 month follow-up, symptoms were reduced by 40% and quality of life improved by 13%.
According to the authors, “preliminary findings support that psilocybin-assisted treatment was feasible and well-tolerated among the sample. Clinical outcomes indicated potentially long-lasting benefits of psilocybin-assisted treatment, warranting further investigation for [chronic Lyme disease].”
Maria Sabina was the first known shaman to allow Westerners, including Aldous Huxley and John Lennon, to participate in the Mazatec psilocybin ritual.
If you enjoy our newsletter, please forward it to your friends!
This newsletter is curated and published by:
Haven’t subscribed yet? Subscribe now!
Reply